IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TRW

In re Application of MICHAELIS, et al.

Application No.: 10/642,974

Filed: August 18, 2003

Title: Use of I kappa B-kinase Inhibitors in Pain

Therapy

Examiner:

Art Unit:

1616

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

Benée M. Him

Signature

<u>INFORMATION DISCLOSURE STATEMENT</u> <u>UNDER 37 C.F.R. 1.56, 1.97 AND 1.98</u>

Mail Stop Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

 \boxtimes

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

ا	(0)	1 1115	s information Discrosure Statement is fried after the period set forth in 37 C.F.K.
		1.97	(b), but is believed to be filed before the mailing date of a final action under §1.113
		or a	notice of allowance under §1.311, whichever occurs first.
		(1)	The undersigned attorney certifies that each item of information contained in this
			Information Disclosure Statement was cited in a communication from a foreign
			patent office in a counterpart foreign application not more than three months prior
			to the filing of this statement;
		(2)	The undersigned attorney certifies that no item of information contained in this
			Information Disclosure Statement was cited in a communication from a foreign
			patent office in a counterpart foreign application or, to the knowledge of the
			undersigned attorney after making reasonable inquiry, was known to any
			individual designated in §1.56(c) more than three months prior to the filing of this
			statement; or
		(3)	This Information Disclosure Statement is accompanied by a transmittal letter in
			which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is
			authorized.

Applicants submit US equivalents for the following: =

WO 01/00610 = US Patent No. 6,358,978

WO 01/30774 = US Publication NO. 2003/0119820

WO 04/022553 = US Pending Application No. 10/642,970

WO 01/68648 = US Patent No. 6,627,637

Respectfully submitted,

September 21, 2004

ulie Anne Knight, Beg. No. 48,867

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3679
Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0064 US NP

Please type a plus sign (+) inside this box 📑

→	1	
	•	

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2


Co	omplete if Known	
Application Number	10/642,974	
Filing Date	08-18-2003	
First Named Inventor	MICHAELIS, et al.	
Group Art Unit	1616	
Examiner Name		
Attorney Docket Number	DEAV2002/0064 - US - NP	

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Number	ment d Code ² (nown)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		6,358,978		RITZELER, et al.	03-19-2002			
		2003/0119820		RITZELER, et al.	06-26-2003			
		6,627,637		RITZELER, et al.	09-30-2003			
		10/642,970		RITZELER, et al.	N/A			
		60/570,146		HADDAD, et al.	N/A			
		10/842,427		RITZELER, et al.	N/A			
					İ			
						Ţ,		
		··-						
	-		1	<u></u>				
					1			

				FORE	IGN PATENT DOCUMENT	TS		
Examiner Initials	Cite No.1		Foreign Patent Do		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	
		Office ³	Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ₆
-								<u> </u>
							<u> </u>	_
		<u> </u>						-
		 				 - 		+
								1

	-	A contract of the contract of
Examiner	Date	
Signature	Considered	

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.





^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box 🛶	/
---	---

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031


Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known			
				Application Number	10/642,974		
NF	ORMATIO		ISCLOSURE	Filing Date	08-18-2003		
STA	TEMENT	RY	APPLICANT	First Named Inventor	MICHAELIS		
. . ,			/ (i i Lio/(ii)	Group Art Unit	1616		
	(use as many	shee	ts as necessary)	Examiner Name			
eet	2	of	2	Attorney Docket Number	DEAV2002/0064 - US - NP		

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the artic item (book, magazine, journal, serial, symposium, catalog, etc.), date, publisher, city and/or country where publi	page(s), volume-i		T²	
		HOTTELET, et al., Development of IkB Kinase Inhibitors As Anti-Inflar Research Supplemental, page 2, (2000), S91, XP009023847	mmatory Therap	peutics, Inflammation		
		YIN, et al., The Anti-Inflammatory Agents Aspirin And Salicylate Inhibit MacMillan Journals Ltd. Vol. 39615, Pages 77-80, (1998), XP002938		IkB Kinase-Beta, Nature,		
Examine Signature	1		Date Considered			

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.





^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.